Keyphrases
Chemotherapy
55%
Breast Cancer
52%
Overall Survival
50%
Tumor
44%
Phase II Trial
38%
Cancer Treatment
34%
Clinical Trials
34%
Confidence Interval
34%
Prostate Cancer
29%
Phase II Study
28%
Treatment Group
24%
Metastatic Colorectal Cancer (mCRC)
24%
North Central
23%
Hazard Ratio
23%
Progression-free Survival
22%
Metastatic Castration-resistant Prostate Cancer (mCRPC)
21%
In Cancer
19%
Placebo
19%
Non-small Cell Lung Cancer (NSCLC)
19%
Ovarian Cancer
18%
Colorectal Cancer
18%
Bevacizumab
17%
Adverse Events
17%
Metastatic Breast Cancer
16%
Mayo Clinic
16%
Cisplatin
16%
Quality of Life
16%
Adjuvant Therapy
16%
5-fluorouracil (5-FU)
16%
Radiation Therapy
16%
Paclitaxel
16%
Oxaliplatin
15%
Early Breast Cancer
15%
Prostate-specific Antigen
15%
Cancer Patients
15%
Gemcitabine
14%
Disease-free Survival
14%
Clinical Outcomes
14%
Radiotherapy
13%
Adjuvant Chemotherapy
13%
Lung Cancer
13%
Oncology
13%
Patients with Cancer
13%
Phase I Study
13%
Postmenopausal Women
13%
Randomized Trial
12%
Hot Flashes
12%
NCCTG
12%
Metastatic Disease
11%
Programmed Death-ligand 1 (PD-L1)
11%
Systemic Therapy
11%
Human Epidermal Growth Factor Receptor 2 (HER2)
11%
Prognostic Factors
11%
Antitumor Activity
10%
Disease Progression
10%
Median Overall Survival
10%
Docetaxel
10%
Endocrine Therapy
10%
Breast Cancer Survivors
10%
High Risk
10%
Breast Cancer Risk
10%
Response Rate
10%
Partial Response
10%
Breast Cancer Patients
10%
Irinotecan
9%
Targeted Therapy
9%
Aromatase Inhibitors
9%
Cyclophosphamide
9%
Glioblastoma
9%
Metastasis
9%
Breast
9%
Maximum Tolerated Dose
9%
Doxorubicin
9%
Colon Cancer
9%
Castration-resistant Prostate Cancer
9%
Odds Ratio
9%
Leucovorin
9%
Chemotherapy-induced Peripheral Neuropathy
9%
Carboplatin
9%
Phase I Trial
8%
Advanced Solid Tumors
8%
Capecitabine
8%
Circulating Tumor DNA (ctDNA)
8%
Pharmacokinetics
8%
Immune Checkpoint Inhibitors
8%
Fluorouracil
8%
Malignancy
8%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
8%
Solid Tumors
8%
Triple-negative Breast Cancer
8%
United States
8%
Advanced Prostate Cancer
8%
Stage III Colon Cancer
8%
Survivors
8%
Cancer Therapy
8%
Cancer Clinical Trials
8%
Pembrolizumab
8%
Estrogen
8%
Nausea
7%
Trastuzumab
7%
Medicine and Dentistry
Breast Cancer
100%
Malignant Neoplasm
72%
Neoplasm
70%
Diseases
48%
Overall Survival
47%
Prostate Cancer
39%
Clinical Trial
36%
Radiation Therapy
32%
Oncology
30%
Metastatic Carcinoma
28%
Cancer Therapy
27%
Recurrent Disease
25%
Cancer
23%
Ovarian Cancer
22%
Progression Free Survival
21%
Colorectal Carcinoma
17%
Hazard Ratio
17%
Quality of Life
16%
Biological Marker
16%
Lung Cancer
16%
Adverse Event
16%
Arm
15%
Placebo
15%
Adjuvant Therapy
15%
Non Small Cell Lung Cancer
15%
Hormone Therapy
13%
Castration Resistant Prostate Cancer
13%
Tamoxifen
13%
Neuroendocrine Tumor
12%
Glioblastoma
12%
Systemic Therapy
12%
Colon Carcinoma
12%
Treatment Group
12%
Disease Free Survival
11%
Adjuvant Chemotherapy
11%
Immunotherapy
11%
Ganglioglioma
11%
Metastatic Colorectal Cancer
10%
Phase II Trials
10%
Melanoma
10%
Targeted Therapy
10%
Bevacizumab
9%
Cisplatin
9%
Prostate Specific Antigen
9%
Paclitaxel
9%
Prognostic Factor
8%
Pancreas Cancer
8%
Hormone Receptor
8%
Estrogen Receptor
8%
Cancer Cell
8%
Aromatase Inhibitor
8%
Metastatic Breast Cancer
8%
Triple Negative Breast Cancer
7%
Oxaliplatin
7%
Clinician
7%
Cholangiocarcinoma
7%
Krukenberg Tumor
7%
Biopsy Technique
7%
Gemcitabine
7%
Xenograft
7%
Epidermal Growth Factor Receptor
7%
Neoadjuvant Chemotherapy
6%
Oncologist
6%
Meta-Analysis
6%
Survival Rate
6%
Postmenopause
6%
Immune Checkpoint Inhibitor
6%
Systematic Review
6%
Circulating Tumor DNA
6%
Small Cell Lung Cancer
6%
Pembrolizumab
6%
Chemoradiotherapy
6%
Randomized Clinical Trial
6%
Fluorouracil
6%
Cancer Risk
6%
Odds Ratio
6%
Adenocarcinoma
6%
Carboplatin
5%
Neoadjuvant Therapy
5%
Connective Tissue Cancer
5%
Proportional Hazards Model
5%
Disease Exacerbation
5%
Bone Metastasis
5%
Liver Metastasis
5%
Hepatocellular Carcinoma
5%
Hot Flush
5%
Letrozole
5%
Carcinogenesis
5%
Primary Tumor
5%
Pancreas Adenocarcinoma
5%
Gamma Urogastrone
5%
Cancer Treatment
5%
Magnetic Resonance Imaging
5%
Doxorubicin
5%
Neuropathy
5%
Phase III Trials
5%
Androgen
5%
Lutetium 177
5%
Pooled Analysis
5%
Tumor Progression
5%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
89%
Chemotherapy
72%
Breast Cancer
65%
Neoplasm
63%
Overall Survival
46%
Diseases
44%
Clinical Trial
38%
Prostate Cancer
37%
Adverse Event
26%
Progression Free Survival
25%
Placebo
24%
Colorectal Carcinoma
21%
Castration Resistant Prostate Cancer
21%
Treatment Group
20%
Metastatic Colorectal Cancer
19%
Solid Malignant Neoplasm
19%
Paclitaxel
18%
Non Small Cell Lung Cancer
18%
Phase II Trials
18%
Fluorouracil
18%
Tamoxifen
16%
Biological Marker
16%
Cisplatin
16%
Pharmacokinetics
15%
Recurrent Disease
15%
Bevacizumab
15%
Metastatic Breast Cancer
14%
Oxaliplatin
14%
Glioblastoma
14%
Colon Carcinoma
14%
Gemcitabine
13%
Lung Cancer
13%
Androgen
11%
Ovary Cancer
11%
Disease Free Survival
10%
Prostate Specific Antigen
10%
Docetaxel
10%
Epidermal Growth Factor Receptor
10%
Doxorubicin
10%
Carboplatin
10%
Irinotecan
9%
Cyclophosphamide
9%
Folinic Acid
9%
Hot Flush
9%
Pancreas Cancer
9%
Maximum Tolerated Dose
9%
Disease Exacerbation
9%
Antitumor Activity
8%
Immunotherapy
8%
Phase III Trials
8%
Endocrine Therapy
8%
Hormone Receptor
8%
Aromatase Inhibitor
8%
Small Cell Lung Cancer
8%
Capecitabine
7%
Estrogen Receptor
7%
Advanced Cancer
7%
Melanoma
7%
Neutropenia
7%
Receptor
7%
Diarrhea
7%
Neuropathy
6%
Randomized Clinical Trial
6%
Gamma Urogastrone
6%
Phase I Trials
6%
Liver Cell Carcinoma
6%
Neuroendocrine Tumor
6%
Anorexia
6%
Chemoradiation Therapy
6%
Combination Therapy
6%
Pembrolizumab
6%
Adenocarcinoma
6%
Tolerability
6%
Monotherapy
6%
Epidermal Growth Factor Receptor 2
6%
Carcinogenesis
5%
Taxane
5%
Measles Virus
5%
Trastuzumab
5%
Sorafenib
5%
Vasculotropin
5%
Survival Rate
5%
Letrozole
5%
Chemotherapy-Induced Peripheral Neuropathy
5%
Bone Metastasis
5%
Nausea
5%
Triple Negative Breast Cancer
5%
Pancreas Adenocarcinoma
5%
Group Trial
5%
Bile Duct Carcinoma
5%